Prognostic implication of a focal lesion of bone marrow in diffuse large В cell lymphosarcoma

Cite item

Full Text


Aim. To study prognostic implications of a focal mature cell lesion of the bone marrow (BM) in patients with diffuse large В cell lymphosarcoma (DBLCL).
Material and methods. 54 patients with histologically confirmed DBLCL were given first-line CHOP and CHOP-like courses from 1996 to 2003. B-cell nature of the tumor was confirmed immunohistochemically, immunophenotypically and with flow fluorimetry.
Results. In debute of the disease 16 patients had local involvement of the lymph organs (stage I-II by Enn-Arbor), 21 patients - generalized disease (stage III-IV) and 17 patients - involvement of nonlymphatic organs. Overall 3-year survival in first-line therapy in mature cell lesion of BM was 23%, without it - 0%. One-year event-free survival was 34 and 0%, respectively.
Conclusion. The presence of a focal mature cell lesion of BM in DBLCL patients influences the prognosis. Regarding high frequency of transformation of mature cell lymphoproliferative diseases in DBLCL . focal lesion of BM is an indirect sign of a secondary nature of the disease.


  1. Harris N. L., Jaffe E. S., Diebold J. et al. World Health Organization classification diseases of the hematopoetic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997. J. Clin. Oncol. 1999; 17 (12): 3835-3849.
  2. Поддубная И. В. Неходжкинские лимфомы. В кн.: Волкова М. А. (ред.) Клиническая онкогематология. М.: Медицина; 2000. 336-376.
  3. Barrans S., Carter I., Morgan G. J. et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell fymphopma. Blood 2002; 99 (4): 1136-1142.
  4. Mounter N., Briere J., Gisselbrecht С. et al. Rituximab plus CHOP (R+CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma. Blood 2003; 6: 1-26.
  5. Philip Т., Blay B. J., Gomez F. et al. The Internaional index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PHARMA trial. Blood 1998; 92 (10): 3562-3568.
  6. Wilder R. В., Rodriguez M. A., Medeiros L. J. et al. International prognostic index-based outcomes for diffuse large B-cell lymphomas. Cancer 2002; 94 (12): 3080-3088.
  7. A predictive model for aggressive non-Hodgkins lymphoma. N. Engl. J. Med. 1993; 329 (14): 987-994.
  8. Moller M. В., Christensen В. Е., Pedersen N. T. Prognosis of localized diffuse large B-cell lymphoma in younger patiens. Cancer 2003; 98 (3): 516-521.
  9. Moller M. В., Pedersen N. Т., Christensen В. Е. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation - a population-based study of 1575 cases. Br. J. Haematol. 2004; 124 (2): 151-159.
  10. Huang J., Sanger G., Greiner T. et al. The t(14; 18) defines a unique subset of large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002; 99 (7): 2285-2290.
  11. Воробьев А. И. Руководство по гематологии. М.: Ньюдиамед; 2002-2003.
  12. Kremer M., Spitzer M., Mandl-Weber S. et al. Discordant bone marrow involvement in diffuse large B-cell lymphoma: Comparative molecular analysis reveals a heterogeneous group of disorders. Lab. Invest. 2003; 83 (1): 107-114.
  13. Guttamacher A. E., Francis S., Collins M. D. et al. Molecular diagnosis of the hematologic cancers. N. Engl. J. Med. 2003; 348: 1777-1785.
  14. Gisselbrecht C., Lepage E., Molina T. et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J. Clin. Oncol. 2002; 20 (10): 2472-2479.

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies